Abstract
Background
Alpha-fetoprotein (AFP)-secreting hepatocellular carcinomas (HCC) represent a genetically distinct subset of tumors often associated with a worse prognosis. However, the molecular mechanisms that underlie these phenotypic differences remain poorly understood.
Methods
HCC tumor samples from 27 patients were profiled using the Affymetrix 133 Plus 2.0 GeneChips. GeneGO Metacore software was used to identify altered biologic pathways. Expression validation was confirmed by RT-PCR. Manipulation of miR-675 by overexpression and antagomir-mediated knockdown was carried out with subsequent evaluation of effects on cell behavior by cell cycle, proliferation, invasion, and growth in soft agar assays.
Results
We identified a strong relationship between primary tumor H19 gene expression and elevated serum AFP. H19 has recently been identified to encode microRNA-675 (miR-675), and we confirmed the relationship in an independent sample of patients. Pathway analyses of the effect of miR-675 overexpression in hepatoma cells revealed a predominant upregulation of cell adhesion and cell cycle initiation pathways. We have demonstrated that miR-675 mediates increases in proliferation and an accumulation of cells with tetraploid DNA content associated with a repression of Rb. We also demonstrated that overexpression of miR-675 alters cellular morphology, reduces invasive potential, and increases anchorage-independent growth capacity. These findings are consistent with a mesenchymal-to-epithelial transition, associated with a reduction in the expression of the key EMT mediator, Twist1.
Conclusions
Expression of the miR-675 in hepatocellular carcinoma links a dramatic upregulation of proliferative and growth capacity with inhibition of motility in HCC cells.
Similar content being viewed by others
References
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–7.
Benson AB, 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Cancer Netw. 2009;7:350–91.
Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31:302–8.
Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69:7385–92.
Takayasu K, Arii S, Ikai I, Omata M, Okita K, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461–9.
Taketa K Alpha-fetoprotein: reevaluation in hepatology. Hepatology 1990;12:1420–32.
Budhu A, Forgues M, Ye QH, Jia HL, He P, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99–111.
Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410–6.
Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007;45:938–47.
Dudich E, Semenkova L, Gorbatova E, Dudich I, Khromykh L, et al. Growth-regulative activity of human alpha-fetoprotein for different types of tumor and normal cells. Tumour Biol. 1998;19:30–40.
Li MS, Li PF, Yang FY, He SP, Du GG, et al. The intracellular mechanism of alpha-fetoprotein promoting the proliferation of NIH 3T3 cells. Cell Res. 2002;12:151–6.
Wang XW, Xu B Stimulation of tumor-cell growth by alpha-fetoprotein. Int J Cancer 1998;75:596–9.
Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res. 2008;68:2391–9.
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249–64.
Elahi A, Zhang L, Yeatman TJ, Gery S, Sebti S, et al. HPP1-mediated tumor suppression requires activation of STAT1 pathways. Int J Cancer 2008;122:1567–72.
Tsang WP, Ng EK, Ng SS, Jin H, Yu J, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 2010;31:350–8.
Yoshimizu T, Miroglio A, Ripoche MA, Gabory A, Vernucci M, et al. The H19 locus acts in vivo as a tumor suppressor. Proc Natl Acad Sci USA 2008;105:12417–22.
Berteaux N, Lottin S, Monte D, Pinte S, Quatannens B, et al. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem. 2005;280:29625–36.
Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-Lail R, et al. The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta 2010;1803:443–51.
Gentric G, Desdouets C, Celton-Morizur S Hepatocytes polyploidization and cell cycle control in liver physiopathology. Int J Hepatol. 2012;28:2430.
Margolis RL Tetraploidy and tumor development. Cancer Cell 2005;8:353–4.
Gabory A, Jammes H, Dandolo L The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays 2010;32:473–80.
Wu J, Qin Y, Li B, He WZ, Sun ZL Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma. Genomics 2008;91:443–50.
Li J, Ran C, Li E, Gordon F, Comstock G, et al. Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Dev Cell 2008;14:62–75.
Lottin S, Adriaenssens E, Dupressoir T, Berteaux N, Montpellier C, et al. Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis 2002;23:1885–95.
Kruger J, Rehmsmeier M RNAhybrid: microRNA target prediction easy, fast and flexible. Nucl Acids Res. 2006;34:W451–4.
Baum B, Settleman J, Quinlan MP Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol. 2008;19:294–308.
Thiery JP, Sleeman JP Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.
Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial–mesenchymal transition. Clin Cancer Res. 2006;12:5369–76.
Matsuo N, Shiraha H, Fujikawa T, Takaoka N, Ueda N, et al. Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer 2009;9:240.
Gunasinghe NP, Wells A, Thompson EW, Hugo HJ Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev. 2012; 31:469–78.
Lustig-Yariv O, Schulze E, Komitowski D, Erdmann V, Schneider T, et al. The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene? Oncogene 1997;15:169–77.
Rachmilewitz J, Elkin M, Rosensaft J, Gelman-Kohan Z, Ariel I, et al. H19 expression and tumorigenicity of choriocarcinoma derived cell lines. Oncogene 1995;11:863–70.
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927–39.
Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 2009;50:1464–74.
Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, et al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213:374–83.
Yang J, Weinberg RA Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818–29.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704–15.
Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, et al. Generation of breast cancer stem cells through epithelial–mesenchymal transition. PLoS One 2008;3:e2888.
Peinado H, Olmeda D, Cano A Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415–28.
Acknowledgment
This work was supported in part by a Grant from the National Institutes of Health (NIH) (R01 CA112215 to J.M.H. and T.Y.)
Author information
Authors and Affiliations
Corresponding author
Additional information
J. M. Hernandez and A. Elahi contributed equally to this work and therefore share first authorship.
Electronic supplementary material
Below is the link to the electronic supplementary material.
10434_2013_3106_MOESM2_ESM.jpg
Supplemental Fig. 1 Kaplan–Meier survival curves for AFP-secreting and non-AFP-secreting HCC. Note: four patients were lost to follow-up and therefore were not included in the analysis. (JPEG 1238 kb)
Rights and permissions
About this article
Cite this article
Hernandez, J.M., Elahi, A., Clark, C.W. et al. miR-675 Mediates Downregulation of Twist1 and Rb in AFP-Secreting Hepatocellular Carcinoma. Ann Surg Oncol 20 (Suppl 3), 625–635 (2013). https://doi.org/10.1245/s10434-013-3106-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-013-3106-3